Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Injective Rallies 10% as Gulf Labs Alliance Fuels Breakout Hopes for INJ

Injective Rallies 10% as Gulf Labs Alliance Fuels Breakout Hopes for INJ

CryptonewslandCryptonewsland2026/10/17 10:12
By:Cryptonewsland
  • INJ gained 10% after Gulf Labs joined Injective as an institutional validator.
  • Trading volume, Open Interest, and active addresses all rose significantly.
  • A breakout above channel resistance could confirm stronger bullish momentum.

Injective has caught traders’ attention after a strong five-day recovery lifted prices roughly 10%. Fresh optimism followed a new partnership announcement with Gulf Labs, adding another layer of confidence to an already improving market structure. Rising trading activity, growing network participation, and stronger derivatives data have helped fuel bullish sentiment. Now, investors are watching closely to see whether INJ can finally break free from a lengthy consolidation phase.

Gulf Labs Partnership Strengthens Market Confidence

Injective recently announced a partnership with Gulf Labs, which joined the network as an institutional validator. This development strengthens network security while expanding participation in governance activities. The collaboration also creates opportunities to explore tokenization, stablecoins, and institutional on-chain finance. The announcement arrived at a favorable time for the market.

INJ had already shown strength after bouncing from support near the 50-day exponential moving average around $6.05. Buyers continued stepping into the market, helping extend gains over several consecutive sessions. Trading volume has also increased sharply. A 25% jump pushed volume to approximately $153.37 million. Such growth suggests stronger participation from traders and investors.

Increased activity often supports bullish momentum, especially when price trends are higher at the same time. Market participants appear encouraged by both the technical setup and the recent institutional development. Together, these factors have added fresh energy to the ongoing recovery.

Rising Activity Points Toward a Potential Breakout

Beyond price action, on-chain metrics also support the improving outlook. Open Interest climbed significantly to roughly $72.45 million during the past day. Higher Open Interest often signals growing confidence among leveraged traders who expect further price movement. Network activity also continues moving in the right direction. Active addresses have increased steadily for nearly a week. Such growth indicates rising engagement across the ecosystem and stronger user participation.

Despite these positive signs, INJ remains inside a channel consolidation pattern. The recent rally has pushed price closer to the upper boundary of that structure. Traders often view this area as a critical test. A successful move above resistance, supported by strong volume, could confirm a bullish breakout. Such a development would strengthen the technical picture and potentially attract additional buyers. However, resistance remains an important obstacle. If buyers fail to push through the upper boundary, consolidation could continue.

The partnership news and improving metrics may support sentiment, but price still needs confirmation through a decisive breakout. For now, momentum favors the bulls. Volume growth, rising Open Interest, and increasing active addresses all support the recovery narrative. The Gulf Labs partnership adds another positive catalyst. The next major test will be whether buyers can convert growing optimism into a confirmed breakout above the current trading range.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23